Header: Digital pathology at warp speed - Tempus acquires Paige, Roche aquires PathAI, ArteraAI gets a true FDA application (Breast cancer prognostics). What should ArteraAI do next? I asked Claude Opus 4.7 to write a guest column.
###
1. Overview
2. ArteraAI Options Map
3. What a CEO Thinks at Night
4. Using High-Low Scenario Modeling
####
1. Overview
Three AI Pathology Companies — Acquisitions, ArteraAI's Story, and Exit Landscape
Recent AI pathology acquisitions
Tempus → Paige (Aug 2025). Tempus AI acquired Paige, an AI digital pathology company, for $81.25 million, paid predominantly in Tempus common stock plus assumption of Paige's remaining Microsoft Azure commitment. Paige brought a dataset of nearly 7 million digitized pathology slides licensed from Memorial Sloan Kettering, plus a foundation model trained on more than 2.3 million whole-slide images. Tempus then launched Paige Predict in January 2026, an H&E-based biomarker prediction suite covering 123 biomarkers across 16 cancer types. Tempus AI + 2
Roche → PathAI (May 7, 2026). Roche agreed to acquire PathAI for up to $1.05 billion: $750M upfront plus up to $300M in milestone payments, with closing expected in the second half of 2026. The deal builds on a partnership established in 2021 and expanded in 2024 for AI-enabled companion diagnostic algorithms; PathAI will fold into Roche's Diagnostics division. Roche specifically wanted PathAI's Image Management System (IMS) and intends to scale it globally, pairing it with Roche's companion-diagnostics franchise. MedTech Dive + 2
The price gap is striking — roughly 13x — and reflects what each buyer was actually paying for. Tempus got a data set and a team that complement an existing oncology platform; Roche got a productized lab IT layer (AISight IMS) plus five years of co-developed companion diagnostics for its drug pipeline.
ArteraAI — origins, work, goals
(ArteraAI is a Los Altos prostate cancer company. There's a separate, unrelated Santa Barbara company called Artera.IO doing patient communications that recently raised $65M.)
Origins. ArteraAI was founded in 2021 with the goal of using AI to globally personalize medical decisions and improve outcomes for cancer patients, built on the belief that histopathology images contain signals that traditional gene-expression tests miss. CEO and co-founder Andre Esteva is well known in medical AI (lead author of the 2017 Nature dermatology-AI paper at Stanford). The company emerged from stealth in March 2023 with $90 million in funding from Coatue, Johnson & Johnson Innovation, Marc Benioff and others. A further $20M followed in February 2024, bringing total raised to roughly $110M. Amazon Web Services + 2
The work. Artera's multimodal AI (MMAI) platform combines digital biopsy images with clinical variables; the algorithm was developed using thousands of patients and tens of thousands of pathology slides, clinically validated across multiple Phase 3 randomized trials. The flagship ArteraAI Prostate Test estimates 10-year risk of distant metastasis and prostate-cancer-specific mortality and predicts hormone-therapy benefit. The SaMD version of their prostate test received FDA De Novo authorization on July 31, 2025. ArteraAI See 24 page FDA review.
Goals. Beyond prostate, the long-term goal is a pan-tumor foundation model that can assess risk and therapy benefit across any cancer sample, starting with breast cancer. Amazon Web Services
Breast cancer — SABCS 2025 abstract data
Artera presented three abstracts at the San Antonio Breast Cancer Symposium (SABCS), December 9–12, 2025. The studies leveraged data from four independent Phase III trials across Germany, Austria, and North America, validating the MMAI model across more than 7,000 patients with HR+ early breast cancer. 01net
The headline finding was from the NSABP B-20 analysis: among patients aged 50 and older, MMAI high-risk individuals experienced a 52% relative reduction in 10-year distant metastasis with chemotherapy, while MMAI low-risk patients derived no additional benefit. This is the predictive (not just prognostic) claim — the same kind of "who actually benefits from treatment" question that made Oncotype DX a multi-billion-dollar franchise in breast cancer. Morningstar
A separate development abstract used data from over 12,000 patients enrolled in six Phase III trials in the US, Germany, and Austria to build the MMAI model for predicting distant metastasis in HR+ early-stage invasive breast cancer. BioSpace
The breast test currently started a laboratory-developed test (the AMA Cat III code application for "AI prognosis of HR+/HER2- breast cancer" was pending as of Apr 30–May 2). The SABCS data package looks deliberately constructed to support both an FDA filing and the NCCN/payer evidence bar for commercial coverage.
###
###
2. Capital and Exit Options.
ArteraAI: Fundraising, Development, and Exit Options
Where Artera stands today
ArteraAI is now a meaningfully different company than it was a year ago. As of May 2026, it has:
- Two FDA authorizations: ArteraAI Prostate (De Novo, July 2025) and ArteraAI Breast (510(k), May 6, 2026) — the first and only FDA-cleared digital pathology-based risk stratification tools in either indication.
- European regulatory access: CE marks under EU IVDR for both the prostate biopsy assay and breast cancer assay (April 2026).
- A Predetermined Change Control Plan (PCCP) allowing iterative model updates without new submissions.
- NCCN guideline inclusion for prostate (since early 2024), with breast inclusion in NCCN as the logical next push.
- Medicare payment [pricing] on claims for the prostate LDT, with CPT code 0376U effective since April 2023.
- Commercial coverage by 73 health plans covering 70.1M lives (as of March 2026), including Anthem and Concert Genetics.
- Approximately $110M raised across seed and follow-on rounds from Coatue, Johnson & Johnson Innovation, Marc Benioff, Prosperity7 Ventures and others, with the last disclosed round being a $20M extension in February 2024.
The strategic picture: Artera now has a regulated multi-cancer AI pathology platform, not just a single product. That distinction drives valuation.
Why the timing is unusually favorable
Three external developments have re-set the market for an asset like Artera:
- Roche / PathAI (May 2026) — up to $1.05B ($750M upfront + $300M milestones) for a company that did not have an FDA-authorized SaMD prognostic device or NCCN-recommended status. This is the most directly relevant comp.
- Tempus / Paige (August 2025) — $81.25M, mostly stock, for a data-and-team asset. Smaller, but it removed one of Artera's most visible competitors and demonstrated public-market acquirers are active.
- Consolidation pressure — with two of the four most-recognized AI pathology names now inside large strategics, the remaining standalone universe is small, which makes scarcity work in Artera's favor.
Path 1: Late-stage growth round
The most straightforward near-term option. Every diagnostics-investor underwriting checkbox has now been ticked: FDA authorization (twice), CE marking, guideline inclusion, Medicare payment, commercial coverage, PCCP, and a second indication validated in Phase 3 data.
- Likely size: $75–150M Series C/D range, depending on dilution tolerance.
- Likely investors: existing investors plus crossover funds (T. Rowe, Fidelity, RA Capital, Perceptive) that typically come in pre-IPO for diagnostics.
- Valuation argument: PathAI comp + dual FDA + reimbursement traction supports a meaningful step-up from the last round.
- Use of proceeds: breast commercial launch, CPT coding and payer coverage for breast, international expansion under CE mark, and continued platform expansion to additional tumor types.
- Risk: a growth round preserves optionality but doesn't lock in value at today's elevated comp environment.
Path 2: Strategic acquisition
The exit pathway most directly supported by the Roche/PathAI comp. Logical acquirers fall into three buckets:
Diagnostics incumbents include
- Exact Sciences — Oncotype DX is the direct target of ArteraAI Breast. Same-day, image-only, in-lab results competing with a send-out genomic test is exactly the disruption Exact would want to own rather than fight.
- Veracyte — already competes with Artera SaMD in prostate guidelines via Decipher; offensive or defensive logic both apply.
- Agendia (MammaPrint) — smaller, threatened, less likely as buyer than as competitor.
- Myriad Genetics, Natera — adjacent diagnostics platforms might consider for pathology AI exposure.
Pharma/diagnostics with companion-diagnostic strategy
- Roche — just spent $1.05B on PathAI, but Artera's FDA-cleared prognostic SaMD with guideline inclusion is a different asset class. Possible, though probably not in the next 12 months.
- Scanner and stack companies (Fujitsu, Danaher, others) — scanner and lab-IT footprint, no flagship AI pathology asset.
- AstraZeneca, Novartis, BMS — pharma with strong oncology pipelines seeking companion diagnostic capability.
Public AI/data oncology platforms
- Tempus — already moved with Paige, but an FDA-authorized SaMD with NCCN inclusion is the kind of tuck-in they buy.
Likely deal structure: upfront + milestones, similar to PathAI. A reasonable range — using PathAI as the upper bound and adjusting for revenue scale — would be $600M–$1.2B total deal value, with substantial milestone weighting.
Path 3: IPO
Plausible but probably not the first move.
- The Tempus 2024 IPO and the broader diagnostics IPO window have improved, but Artera's revenue scale is likely still below where public investors comfortably underwrite a diagnostics name.
- Better positioned 18–24 months out, after breast claims revenue ramps and coverage broadens.
- IPO valuation discipline tends to undervalue platform stories versus strategic buyers who can quantify cross-sell and synergy.
Path 4: Stay private and build
The "do nothing" option, which is rarely actually nothing.
- Each subsequent milestone — breast CPT code, breast NCCN inclusion, breast payer coverage, third indication clearance — adds enterprise value.
- The risk: pathology AI is consolidating in real time around 2–3 large platforms. A standalone with great technology can still get squeezed on distribution, hospital purchasing committees, and pharma partnership access.
- Best suited if leadership has a specific milestone (e.g., $50M+ ARR or a third FDA clearance) at which they believe a markedly better exit becomes available.
What to watch over the next 6–12 months
- Breast reimbursement milestones: AMA Cat III code decision for HR+/HER2-, CMS pricing, first commercial payer policies.
- NCCN breast guideline inclusion: the single biggest catalyst for breast adoption and payer coverage.
- A third indication: bladder, kidney, or another tumor type would convert "two-product company" to "true platform."
- Strategic process signals: banker hires, named CFO with public-company experience, IPO-track audit firm engagement.
- Pharma partnership announcements: companion-diagnostic deals with large oncology pharma would both generate non-dilutive revenue and signal to acquirers.
Recommended framing
The strongest argument Artera can make right now — to investors or acquirers — is that it is the only company in AI pathology with FDA authorizations in two indications, a regulated change-control mechanism, an established reimbursement footprint in one indication, and a clinically-validated pipeline behind it. That combination did not exist anywhere in the market six months ago, and the recent strategic activity has made it scarce and valuable simultaneously. Whichever path is chosen, the negotiating leverage is at a high-water mark.
###
###
3. Night Thoughts of a CEO
CEO/Chair Memo — Strategic Reflection, Mid-2026
Personal working notes. Not for distribution.
What I'm thinking
We are in the best position this company has ever been in, and probably the best position we will be in for the next 18 months unless we execute nearly perfectly. That asymmetry is the thing I keep coming back to.
Six months ago we were a one-product company with a great FDA story and a real but narrow commercial footprint in prostate. Today we are — credibly, not aspirationally — a regulated multi-cancer AI pathology platform. The market just told us what that's worth: Roche paid up to $1.05B for a company that didn't have what we now have. That comp will not stay fresh forever. Strategic memory in M&A is about 12–18 months; after that, boards anchor to whatever the next deal prints, and the next deal might be smaller.
At the same time, I am acutely aware that "best position ever" is exactly the moment founders most often misread. The temptation is to believe the milestones will keep compounding linearly. They won't. Breast reimbursement is going to be a slog. The Cat III pathway is narrowing for AI [with new rules like AMA Appendix S] and possible enw AMA codes like "CMAA" - tbd.)
Payers have raised the bar. Distribution into hospital pathology labs is harder than my investor SaMD slide deck makes it look. And the consolidation around Tempus/Paige and Roche/PathAI changes the competitive dynamics in ways I don't fully understand yet — particularly around hospital purchasing committees and pharma partnership access.
So the real question isn't "what's the optimal path." It's: what decision do I need to make in the next 90 days that preserves the most optionality if I'm wrong about which path is optimal?
The core dilemma
It comes down to one trade-off, framed three ways:
Financial framing: Raise now at a high mark and dilute, or run a strategic process now and crystallize value, or push through to more milestones and risk the window closing.
Mission framing: I started this company to build a pan-tumor foundation model that personalizes cancer therapy globally. That mission survives — and arguably accelerates — inside Roche or Exact. It also survives independently with more capital. It does not survive a botched solo run that ends in a distressed sale in 2028.
Personal framing: If I sell now, I almost certainly stay on for 2–3 years inside the acquirer, then what? If I raise money and run it, I'm signing up for another 5–7 years minimum with materially higher execution risk. Neither answer is obviously wrong. Both answers have a version where I look back and wish I'd done the other.
Given my bias to an independent Artera, I should discount my own instincts here by maybe 20%.
The pivot points I'm actually weighing
1. Do we run a process now, or wait one more milestone cycle?
Arguments for now: PathAI comp is fresh, scarcity is real, we have the leverage. Arguments for waiting: breast NCCN inclusion plus first commercial payer wins plus a third FDA filing would, in theory, push us from "platform with two indications" to "the AI pathology platform" — and the multiple expansion from that re-rating could be larger than the multiple compression risk from waiting.
The honest answer is I don't know which is bigger. I think they're roughly the same magnitude, which means the tiebreaker is execution risk and team energy, not financial modeling.
2. If we raise, do we take strategic money?
A large pharma or diagnostics player taking a minority stake plus a commercial or co-development deal is the highest-information option I haven't fully explored. It lets us test partnership chemistry with a likely future acquirer without committing.
But it also signals to other potential buyers that we're "spoken for" and can suppress the open-auction dynamic later.
3. What's the right second-product priority?
We've been opportunistic — prostate, then breast because the data was there. The next one matters more strategically. Bladder is the easiest scientifically (we have the Cat III code already approved). Kidney is bigger commercially. A pan-tumor foundation model demo is more impressive to acquirers but takes longer. I don't have a clean answer and I should.
4. Commercial scale-up vs. regulatory/clinical momentum
We've been a regulatory-and-evidence machine. We have not been a commercial machine. Our hospital lab sales motion for the SaMD product is still nascent. If we're staying independent, this is the gap I lose sleep over. If we're selling, the acquirer's salesforce solves it overnight — which is itself an argument for selling, and I should be careful not to use that as a rationalization. Assuming the acquirer's sales force welcomes us and has the right incentives and skills.
5. The team question
I have people who joined to build a generational company. Some of them will be excited by an exit; some will feel sold-out. I have other people who joined for the IPO arc. Some of them will leave if we sell early.
Retention math on an acquisition has to account for who actually stays through the earnout — and a platform's value erodes fast if the AI/ML team scatters. This is not a hypothetical concern; it's the thing that determined whether Paige and PathAI were good buys for their acquirers, and we won't know the answer on those for another year.
What I'd want to know before deciding
In rough priority order:
About the market
- What would ABC actually pay, and would they engage? They're the most natural defensive acquirer for the breast asset and we have no read on their appetite. A quiet, banker-led temperature check would tell us a lot without committing us.
- Is Roche really done after PathAI, or are they buyers of a complementary asset within 12 months? My instinct says they're done for now, but I'd want to test it.
- What did Tempus actually do with Paige post-close? If integration is going well, they're a more credible acquirer for us than the consensus thinks. If it's struggling, they're out for 2+ years.
- Where is DEF strategy heading? They're the one player I can imagine making a competing bid that meaningfully changes our negotiating posture.
About our own business
- What does the realistic breast revenue ramp look like over 24 months, base / bull / bear, given no CPT code yet? I have rough numbers but I want them stress-tested by someone who has actually launched a breast diagnostic before.
- What's our actual hospital lab sales conversion data from the prostate SaMD early access program? Not the happy pitch deck version — the real funnel math. This tells me whether the SaMD commercial motion is working or whether we're still effectively an LDT company with FDA stickers.
- What's the cash runway under each path? I think we have 18–24 months but I want to know what changes if breast launch costs more than planned.
- What's the regulatory cost and timeline for a third indication, and which one maximizes platform narrative versus revenue?
About the buyers and partners
- Who would do a strategic minority investment plus partnership without a path-to-acquisition lockup? This is the highest-leverage structure available to us and I don't know who's actually open to it.
- What's the current pharma appetite for companion diagnostic partnerships specifically built on AI pathology? Post-PathAI, this market should be hotter, but pharma BD cycles are slow.
- For each plausible acquirer: who is the actual decision-maker, what's his/her current strategic agenda, and what's their integration track record?
- Generic "Roche might buy us" is not helpful to me.
- "The Roche Diagnostics SVP, John Smith, who championed PathAI, is now looking for X"… I can move with that.
About the team and myself
- Who on the leadership team has genuinely processed the trade-offs and can give me honest counsel versus telling me what they think I want to hear? The board can do this, but the board doesn't carry the operational weight. I need 2–3 internal voices I trust to push back.
- What do I actually want? This should align but doesn't always, and I'd rather notice the gap now than discover it during a deal.
- What do my co-founders think? Don't assume.
What I'd do in the next 90 days regardless of path
These are no-regret moves:
- Hire a banker on a quiet retainer. Not to run a process — to give us real market intelligence and be ready if we need to move fast. Goldman, Centerview, or Jefferies for the diagnostics specialization.
- Take one or two exploratory meetings. Through the banker, not direct. With ABC and one pharma. Listen, don't pitch. The information value is enormous and the commitment cost is zero.
- Pressure-test the breast launch plan. Bring in 1–2 senior advisors who have personally launched competing diagnostics. Their assessment of our commercial readiness will dominate any board discussion of timing.
- Lock in the AI/ML team. Refreshed equity grants, retention packages, whatever it takes. Whether we sell or scale, the model team is the asset. If they walk, every path gets worse.
- Get the third-indication decision made. Not the work done — the decision. Bladder, kidney, or foundation model demo. Pick one and commit, because indecision here costs us 6 months of narrative.
- Have the conversation with my co-founders and with the board chair separately. Where each of them actually is on the spectrum from "build for a decade" to "take the right offer." I should know this before any banker conversation moves past exploratory.
What I'm not going to do
- I'm not going to start telling people we're "exploring strategic alternatives." The minute that phrase leaks, valuation gets harder and the team starts updating LinkedIn.
- I'm not going to chase a pre-emptive offer. Pre-empts are almost always under-priced; if someone wants us badly enough to pre-empt, they'll pay more in a process.
- I'm not going to over-index on the PathAI comp publicly. It's our anchor internally, but waving it around with bankers and acquirers makes us look like we've already decided to sell.
- I'm not going to let the breast launch get under-resourced because we're distracted by strategic optionality. Whatever path we choose, breast commercial execution is the proof point that justifies our value. A weak launch tanks every other option and outcome.
The honest summary
The right answer is probably: raise a modest strategic round in the next 6 months with optionality built in, run a quiet market check in parallel, and make a binding decision on path by Q1 2027 when we'll have the first 6 months of breast commercial data.
That's not the bold answer. It's not the simple answer. But it's the answer that preserves the most value across the widest range of futures, which is what I'm paid to do.
I should sleep on it. And I should talk to my co-founder before I do anything that locks anything in.
###
###
4. High-Low Scenario Map
Two ArteraAI Scenarios: Mid-2026 to End-2028
Both scenarios assume the same starting point — May 2026, two FDA clearances, ~$110M raised, prostate generating real revenue, breast just cleared. Both are realistic. The point isn't to predict; it's to make the shape of each future concrete enough to plan against.
Upside Scenario: "The Platform Thesis Validates"
Mid-to-late 2026
The breast launch goes better than the board's base case. The hospital lab sales motion built for prostate transfers cleanly — same buyers, same workflow, incremental sell. Within 90 days of launch, three top-20 academic medical centers commit to integrating ArteraAI Breast alongside prostate, and one of them publishes early implementation data showing same-day reporting versus the 5–10 day send-out for Oncotype DX. That single data point becomes the entire commercial pitch.
A late-2026 growth round closes at materially higher valuation than the last mark. The round is led by a crossover fund (T. Rowe or Fidelity), with one strategic — a large pharma, not a diagnostics player — taking a minority position alongside a multi-year companion diagnostics partnership. The strategic stake is structured deliberately without right-of-first-refusal or any acquisition lockup. Total raised crosses $200M. Runway extends to 36 months.
The AMA Cat III code for breast moves through the editorial panel on the first submission, helped by the FDA clearance and the SABCS evidence package. CMS pricing follows the prostate playbook. We start billing Medicare on breast claims in Q2 2027.
Through 2027
NCCN inclusion for ArteraAI Breast in HR+/HER2- early-stage breast cancer arrives in the v2.2027 guidelines. This is the single most important commercial event in the company's history — bigger than either FDA clearance — because it forces payer coverage conversations and unlocks the academic medical center buyer who needs guideline cover to deploy.
A third indication clears FDA via 510(k) by mid-2027. The PCCP infrastructure means the submission takes 8 months instead of 18. The "platform" narrative is no longer marketing — it's three indications, two pathways, and a regulatory mechanism for continuous improvement. This is the moment Artera stops being compared to single-product diagnostics companies and starts being compared to AI platforms.
The pharma partnership generates its first milestone payment in late 2027, validating the companion diagnostic thesis. A second pharma signs a similar deal in Q4. Non-dilutive revenue becomes a real line item.
Commercial revenue hits roughly $60–80M ARR by end of 2027, growing 100%+ year-over-year, with healthy gross margins on the SaMD product and improving margins on the LDT business as volume scales.
Through 2028
Multiple things happen in parallel that compound:
- A fourth indication enters FDA review.
- The foundation model work matures into a demonstrable pan-tumor capability — not commercial yet, but credible enough to anchor investor conversations.
- The hospital lab installed base crosses 200 sites, creating a network effect where new indications can be cross-sold into existing accounts at near-zero CAC.
- A second large pharma partnership expands into a co-development arrangement.
By mid-2028, the company is in a position where three outcomes are simultaneously available:
- A premium strategic acquisition at $2.5–4B. Most likely Roche (returning for a complementary asset to PathAI) or ABC (defensive, expensive). Possibly /PharmaX/ or a non-obvious pharma buyer through the partnership relationship.
- An IPO in a window that opens for diagnostics names with $100M+ ARR, growth above 80%, and a platform story. Underwriters compete for the mandate.
- A continued private path with another late-stage round at a $3B+ valuation, building toward a 2029–2030 outcome.
The luxury of having all three options is the actual prize. The CEO gets to choose based on what serves the mission, not what's available.
Key features of this scenario: Compounding, not breakthrough. No single miracle. Every individual step is something the company has already done at least once — clear FDA, build commercial, secure reimbursement, sign pharma. The success comes from doing all of them in parallel and on time.
Probability assessment: Plausible. Maybe 25–30%. It requires execution at roughly the 70th percentile across six independent workstreams. Each individual workstream is achievable; the conjunction is what makes it hard.
Downside Scenario: "The Slow Squeeze"
Mid-to-late 2026
The breast launch starts slower than projected. Hospital pathology lab procurement cycles are longer than the prostate experience suggested — those early prostate accounts had champions who were already digital pathology believers, and the next cohort doesn't. The first three "easy" accounts take six months to close instead of three.
The growth round happens, but it's smaller than hoped — $75–100M — and the valuation step-up is modest, around 1.5x the last mark rather than the 3x the PathAI comp suggested. The reason isn't the asset; it's the diagnostics financing environment, which softens in late 2026 when a couple of public comps miss earnings. Crossover funds pass. The round is led by existing investors with one new healthcare specialist, which is a flat-to-down signal that the strategic acquirers register.
The AMA Cat III code for breast hits a snag — not a rejection, but a request for revisions that pushes the effective date to 2028. CMS pricing follows the code, so Medicare billing on breast doesn't start when planned.
Through 2027
NCCN inclusion for breast doesn't come in the v2.2027 guidelines. The panel wants longer follow-up on the predictive (chemotherapy benefit) claim, not just the prognostic data. This is a defensible scientific position but a commercial disaster — it pushes inclusion to v2.2028 at earliest, which means most commercial payers won't write coverage policies until 2028, which means hospital lab buyers won't commit volume until coverage exists. The chicken-and-egg problem the slides described is real and we're now living inside it.
Meanwhile, two competitive dynamics get worse:
- Tempus + Paige launches a breast biomarker prediction product as part of Paige Predict, leveraging their existing oncology install base and reference lab relationships. It's not as good clinically but it's bundled into a workflow customers already have. Sales cycles get harder.
- Exact uses glass slide archives, which are plentiful, to develop a test that's additive with Oncotype.
- Announces an AI overlay to Oncotype DX — an "Oncotype DX AI" product that adds image analysis to their existing genomic test.
- It's a defensive product, scientifically weaker than ours, but it carries the brand and the payer contracts. We start hearing it in customer conversations.
A pharma partnership conversation that looked promising in early 2027 stalls. The pharma partner does a similar deal with PathAI/Roche instead, partly because Roche can offer the full integrated companion diagnostic stack and we can offer the AI piece only.
The third indication clears FDA, but later than planned — Q4 2027 instead of mid-year — and the data package was harder to assemble than expected because the right validation cohort wasn't readily available.
Revenue hits ~$30–40M ARR by end of 2027. Growth is real but is below plan, and the gross margin story is muddier than the board deck suggested because hospital lab sales have higher implementation costs than the model assumed.
Through 2028
This is the "downside" forecast, so the squeeze tightens. Three forces compound in the wrong direction:
- Cash burn vs. revenue ramp. With a smaller-than-hoped 2026 round and slower revenue, runway becomes a 2028 problem. A bridge round in mid-2028 happens at flat-to-down valuation, and existing investors have to choose between supporting it and accepting dilution. The signal to outside acquirers is unmistakable.
- Strategic acquirer interest cools. The Roche/PathAI integration is going well enough that Roche is uninterested in a second pathology asset. Tempus is focused on absorbing Paige. Exact's defensive AI product is in market and they no longer feel they need to buy us. The natural buyer set has effectively closed, at least for the next 18 months.
- Talent risk crystallizes. Two senior AI/ML leaders leave for better-funded competitors or to start their own companies. Replacements are findable but the institutional knowledge in the foundation model work degrades. The "platform" narrative gets harder to tell honestly.
By mid-2028, the company faces a harder choice set:
- A strategic acquisition at $400–700M — real money, but a fraction of the PathAI comp and well below what was achievable in 2026. The likely acquirer is a tier-2 diagnostics player or a private equity rollup, not a premium strategic. Founders and early investors do well; later investors are roughly flat.
- A down round at a $600–900M post-money, with new investor protections that materially dilute the founders and reset the cap table.
- A continued grind that buys time but doesn't change the trajectory — eventually leading to option 1 or 2 in 2029 on worse terms.
The IPO option is gone. It doesn't come back until 2029–2030 at earliest, and only with a meaningful inflection that's hard to engineer from this position.
Key features of this scenario: No catastrophe. No FDA rescission, no clinical scandal, no fraud. Just a series of small misses that compound. Each individual miss is recoverable; the conjunction is what creates the squeeze. The company never fails in any dramatic sense. It just becomes worth less than it should have been.
Probability assessment: Equally plausible. Maybe 25–30%. The reimbursement timeline risk is the single biggest swing factor and it's largely outside management's control.
What both scenarios share
Looking at these side by side, three observations matter more than the outcomes themselves:
1. The high-success scenario doesn't require luck — it requires reimbursement to work. The single biggest variable between the two scenarios is whether breast CPT coding, CMS pricing, NCCN inclusion, and commercial payer policy all move on schedule. That entire workstream is partially outside management's control and is the right place to over-invest attention and resources right now.
2. The downside scenario is largely about competitive dynamics, not internal execution. In the bad version, Artera doesn't fail at anything — it gets slowly squeezed by larger, better-distributed competitors. This argues for moving faster on strategic optionality, not slower, because the window where Artera looks scarce and special is open now and may not be open in 18 months.
3. The optionality value of acting in 2026 is asymmetric. A strategic conversation initiated in 2026 from a position of strength can be walked away from if the high-success path materializes. A strategic conversation initiated in 2028 from a position of weakness happens on the acquirer's terms. The cost of optionality is low; the cost of not having it is potentially enormous.
What to plan against
The right planning posture isn't to bet on the high-success scenario or to insure against the downside — it's to set up the 2026 decisions so that:
- If the high-success scenario materializes, the company is positioned to choose among three good outcomes.
- If the downside scenario materializes, the company has already established the relationships and information base needed to execute a strategic sale before the squeeze tightens.
The actions look similar in both cases for the next 6 months: hire the banker, take exploratory meetings, lock in the team, over-resource reimbursement work, get the third-indication decision made. The divergence in tactics happens around Q1 2027, when the first breast commercial data and the NCCN decision will tell management which world they're actually living in.
That's the practical value of running both scenarios — not to predict, but to identify the actions that look right in both, and execute those first.
###
The original output sometimes included mutiple citations widgeted together, the blog here captures the 1st one.
